adaptimmune-logo-color

 

Adaptimmune Therapeutics plc

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient’s own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Nasdaq: ADAP
IR Website: https://www.adaptimmune.com/investors-and-media
Headquarters: United Kingdom


TALK TO MANAGEMENT

The Adaptimmune Therapeutics plc management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

Summary

Investor Presentation

Management Overview

Risks & Disclosures